Moffitt Cancer Center's M2Gen Joins ConvergeHealth in Personalized Cancer Partnership | GenomeWeb

NEW YORK (GenomeWeb News) – Moffitt Cancer Center's subsidiary M2Gen has joined Deloitte's ConvergeHealth in a partnership aimed at using analytics and Moffitt's biomarker data to develop personalized cancer treatments, Deloitte said today.

M2Gen, ConvergeHealth, and Deloitte will work together in a consortium launched by Intermountain Healthcare to contribute to biomarker discovery and genetic clinical trial matching, and to generate evidence to support personalized medicine efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.